DNMT3A and hematologic disorder: Changes in the expression of epigenetic regulators, such as enhancer of zeste 2 polycomb repressive complex 2 subunit (EZH2), myeloid/lymphoid or mixed-lineage leukemia (MLL), isocitrate dehydrogenase 2 (NADP+) mitochondrial (IDH2), tet methylcytosine dioxygenase 2 (TET2) and DNA (cytosine-5-)-methyltransferase 3 alpha (DNMT3A), have been described in hematologic malignancies, including DLBCL, and can have a prognostic value [12–15].